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2012.08.0Abstract Background: SEC is an undifferentiated tumour used in tumour studies. MTX is an
antimetabolite used in treatment of cancer, autoimmune diseases and induction of abortion.
VPA is used as anticonvulsant and is under investigation for treatment of cancer. The aim of this
work was to compare between the effect of each of MTX and VPA on solid Ehrlich tumour in mice.
Methods: Forty albino mice were divided into 4 equal groups: control untreated group, SEC
group, SEC+MTX group, and SEC + VPA group. Tumour volume, tissue CAT, tissue GR, tis-
sue MDA, tissue cholesterol and tissue TNF-a were determined. A part of the tumour was exam-
ined for histopathological and immunohistochemical study.
Results: MTX alone or VPA alone induced a signiﬁcant increase in tissue CAT and GR with a sig-
niﬁcant decrease in the tumour volume, tissue MDA, cholesterol and TNF-a and alleviated the his-
topathological changes with a signiﬁcant increase in p53 expression compared to SEC group. This
effect was more signiﬁcant in MTX treated group compared to VPA treated group.
Conclusion: MTX has more antitumour effect than VPA against SEC.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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01Introduction
Solid Ehrlich tumour is an undifferentiated solid tumour that
is frequently used in tumour studies. It is both used to develop
a tumour model and in chemotherapy investigations [1]. Fol-
lowing subcutaneous injection of Ehrlich tumour cells, a tu-
mour of 1 cm in diameter is obtained approximately within
1 week. This highly virulent tumour causes death of almost
100% of experimental animals in a short period. Large-scale
virulence, quick development and inﬁltrative nature of the tu-
mour reﬂect its high-grade malignancy [2].
Methotrexate (MTX) is an antimetabolite and antifolate
drug used in treatment of cancer, autoimmune diseases and
as an abortifacient in induction of medical abortion [3].and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
162 M.N. Abdel-Rahman, A.M. KabelMTX competitively inhibits dihydrofolate reductase (DHFR),
an enzyme that catalyses the conversion of dihydrofolate to the
active tetrahydrofolate which is needed for DNA synthesis.
MTX, therefore, inhibits the synthesis of DNA, RNA and pro-
teins. MTX is cytotoxic during the S-phase of the cell cycle. So,
it has a greater toxic effect on rapidly dividing cells (such as
malignant and myeloid cells, gastrointestinal and oral muco-
sa), which replicate their DNA more frequently and thus inhib-
its growth and proliferation of these cells as well as causing
many side effects [4].
Valproic acid (VPA) is a chemical compound that has
found clinical use as an anticonvulsant and mood-stabilizing
drug, primarily in treatment of epilepsy, bipolar disorder,0
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Figure 1 Effect of administration of MTX and VPA on tumour volum
cholesterol and tissue TNF-a in SEC treated mice. Values are repr
*Signiﬁcant compared to the control group (P> 0.05). #Signiﬁcant
VPA+ SEC group (P< 0.05).and, less commonly, major depression. It is also used to treat
migraine headache and schizophrenia [5]. Recently, VPA is un-
der investigation for treatment of HIV and various cancers [6].
VPA not only suppresses tumour growth and metastasis, but
also induces tumour differentiation in vitro and in vivo.
VPA increases the DNA binding of activating protein-1 tran-
scription factor, downregulates protein kinase C activity,
inhibits glycogen synthase kinase-3b, activates the peroxisome
proliferator-activated receptors and blocks HDAC (histone
deacetylase), causing hyperacetylation. These ﬁndings eluci-
date an important role of VPA for cancer therapy [7]. The
aim of this work is to compare between the effect of each of
MTX and VPA on solid Ehrlich tumour in mice.0
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e, tissue catalase, tissue MDA, tissue glutathione reductase, tissue
esented as mean ± SEM. Number of mice in each group = 10.
compared to SEC group (P< 0.05). $Signiﬁcant compared to
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Drugs used
 Methotrexate (Methotrexate 50 mg vial, Sanoﬁ Aventis)
was administered by intraperitoneal injection at a dose of
2.5 mg/kg body weight [8].
 Valproic acid (sodium salt; Sigma–Aldrich) was dissolved in
saline and administered by intraperitoneal injection at a
dose of 200 mg/kg body weight [9].
Solid Ehrlich carcinoma (SEC) tumour model
A model of SEC was used, where 1 · 106 of the Ehrlich carci-
noma cells (ECC) obtained from the Pharmacology and Exper-
imental Oncology Unit of the National Cancer Institute, Cairo
University, Egypt were implanted subcutaneously into the right
thigh of the lower limb of mice. A palpable solid tumour mass
(about 100 mm3) was developed within 12 days [10].
Classiﬁcation of animals
In this study, we used 40 mice weighing about 20–25 g. All the
experiments were conducted according to the National Re-
search Council’s guidelines. Animal handling was followed
according to Helsenki declaration of animal ethics. The ani-
mals were divided into 4 equal groups of 10 mice each as
follows:
Group (1): is the control untreated group.
Group (2): Ehrlich tumour cells were implanted subcutane-
ously into the right thigh of the lower limb of mice
[10].
Group (3): MTX was given by intraperitoneal injection on
alternate days for 3 weeks after subcutaneous
implantation of Ehrlich tumour cells into the right
thigh of the lower limb.
Group (4): VPA was given by intraperitoneal injection once
daily for 3 weeks after subcutaneous implantation
of Ehrlich tumour cells into the right thigh of the
lower limb.
Assessment of the effects of different treatments on tumour
volume (TV) of SEC
Tumour volume was measured on days 12, 14, 16, 18, 20 and
22 after implantation of ECC cells using a Vernier caliper (Tri-
cle Brand, Shanghai, China). The following formula was used
to calculate the volume of the developed tumour mass [11]:
Tumour volume ðmm3Þ ¼ 4p A
2
 2
 B
2
 
where A is the minor tumour axis; B the major tumour axis
and p equals to 3.14.
At the end of the study, all mice were sacriﬁced. The tu-
mour was excised and divided into two portions: one for
homogenization and the other for histopathological and
immunohistochemical examination. The tumour was homoge-
nized for determination of tissue catalase according to themethod described by Higgins et al. [12], tissue malondialde-
hyde according to Uchiyama and Mihara [13], tissue glutathi-
one reductase according to the method of Manso and
Wroblewski [14], tissue cholesterol using kits obtained from
Biodiagnostic Co. according to the method of Richmond [15]
and tissue tumour necrosis factor alpha using mouse TNF-a
ELISA kits supplied by RayBiotech Inc. The SEC sections
were prepared and stained with haematoxylin and eosin
(H&E) stain for histopathlogical examination [16]. Immuno-
histochemical staining of p53 in formaline-ﬁxed, parafﬁn
embedded SEC sections was done, using Zymed’s 2nd genera-
tion kit (Histostain-Plus Kit) that utilizes the labelled strep-
tavidin–biotin (LAB-SA) staining methodology (Zymed
Laboratories Inc., Carlton Court, south San Francisco, CA).
Positive nuclei for p53 accumulation stained brown. The tu-
mour was considered to be p53-positive if more than 10% of
cells showed positive staining. The number of cells showing nu-
clear accumulation of p53 in positive tumours was expressed as
follows: (++++): the largest number of cells showing posi-
tive nuclear staining for p53; (+++): intermediate number of
p53-positive cells; (++): indicates lower number of cells with
p53-stained nuclei [17].
Statistical analysis
Data were presented as mean ± SEM, data were analysed by
one way analysis of normality of variance (ANOVA) using stu-
dent t-test, differences between the means of different groups
were considered signiﬁcant at a level of p< 0.05.
Results
Effect of MTX or VPA on tumour volume
– Intraperitoneal administration of MTX or VPA to mice
resulted in a signiﬁcant decrease in tumour volume com-
pared to the group that received subcutaneous implantation
of Ehrlich tumour cells (Fig. 1a). The decrease in tumour
volume was signiﬁcant in the group that was treated with
MTX compared to the group that received VPA.
Effect of MTX or VPA on the antioxidant status
– Subcutaneous implantation of Ehrlich tumour cells into the
right thigh of the lower limb of mice resulted in a signiﬁcant
decrease in tissue catalase and tissue glutathione reductase
with a signiﬁcant increase in tissue MDA compared to the
normal control group (Fig. 1b–d).
– Intraperitoneal administration of MTX or VPA to mice
resulted in a signiﬁcant increase in tissue catalase and tissue
glutathione reductase with a signiﬁcant decrease in tissue
MDA compared to the group that received subcutaneous
implantation of Ehrlich tumour cells (Fig. 1b–d). The
increase in tissue catalase and tissue glutathione reductase
and the decrease in tissue MDA were signiﬁcant in the
group that was treated with MTX compared to the group
that received VPA.
Figure 2a A photomicrograph of Ehrlich solid tumour showing
sheets of small, higher chromatophilic tumour cells of variable
shape representing cell proliferation surrounding areas of necrosis
(H&E · 250).
Figure 2b A photomicrograph of SEC sections from mice that
received MTX showing sheets of malignant cells with focal
necrosis and apoptosis (H&E · 250).
164 M.N. Abdel-Rahman, A.M. KabelEffect of MTX or VPA on tissue cholesterol
– Subcutaneous implantation of Ehrlich tumour cells into the
right thigh of the lower limb of mice resulted in a signiﬁcant
increase in tissue cholesterol compared to the normal con-
trol group (Fig. 1e).
– Intraperitoneal administration of MTX or VPA to mice
resulted in a signiﬁcant decrease in tissue cholesterol com-
pared to the group that received subcutaneous implantation
of Ehrlich tumour cells (Fig. 1e). The decrease in tissue cho-
lesterol was a signiﬁcant in the group that was treated with
MTX compared to the group that received VPA.
Effect of MTX or VPA on tissue TNF-a
– Subcutaneous implantation of Ehrlich tumour cells into the
right thigh of the lower limb of mice resulted in a signiﬁcant
increase in tissue TNF-a compared to the normal control
group (Fig. 1f).
– Intraperitoneal administration of MTX or VPA to mice
resulted in a signiﬁcant decrease in tissue TNF-a compared
to the group that received subcutaneous implantation of
Ehrlich tumour cells (Fig. 1f). The decrease in tissue
TNF-a was signiﬁcant in the group that was treated with
MTX compared to the group that received VPA.
Histopathological ﬁndings
– Subcutaneous implantation of Ehrlich tumour cells resulted
in the development of Ehrlich solid tumour showing sheets
of small, higher chromatophilic tumour cells of variable
shapes representing cell proliferation surrounding areas of
necrosis and differentiated cells (Fig. 2a) with negative
staining for p53 (Fig. 3a). This picture was signiﬁcantly
improved in mice given MTX or VPA as evidenced by
increasing degrees of necrosis (Figs. 2b, 2c), progressively
increasing apoptosis and increased expression of p53 (Figs.
3b and 3c).Figure 2c A photomicrograph of SEC sections from mice that
received VPA showing necrosis and apoptosis (H&E · 250).Discussion
Ehrlich carcinoma is an undifferentiated carcinoma that is
originally hyperdiploid, has high transplantable capability,
no-regression, rapid proliferation, short life span, 100% malig-
nancy and also does not have tumour-speciﬁc transplantation
antigen. Ehrlich carcinoma has a resemblance with human tu-
mours which are the most sensitive to chemotherapy due to the
fact that it is undifferentiated and has a rapid growth rate [18].
Following implantation of Ehrlich tumour cells, morphologi-
cal and metabolic changes occur such as structural deteriora-
tion, decreased number of mitochondria, decreased DNA
and RNA synthesis, loss of intracellular purine and pyrimidine
nucleotides, nucleosides and bases, a decline of ATP concen-
tration and turnover, decreased protein synthesis, decreased
glutathione concentration and increased triglycerides, choles-
terol esters and free fatty acids [19].
In the present study, subcutaneous implantation of Ehrlich
tumour cells into the right thigh of the lower limb of mice re-
sulted in a signiﬁcant decrease in tissue catalase and tissue glu-
tathione reductase with a signiﬁcant increase in tissue MDA,tissue cholesterol and tissue TNF-a compared to the normal
control group. These results were in agreement with Badr
El-Din [20] and Zahran et al. [21]. A number of studies had
indicated that reactive oxygen species (ROS) are involved in
a variety of different cellular processes ranging from apoptosis
and necrosis to cell proliferation and carcinogenesis. In fact,
molecular events, such as induction of cell proliferation,
Figure 3a A photomicrograph of p53 staining of SEC sections
from mice showing negative staining for p53 (PAP · 250).
Figure 3b A photomicrograph of p53 staining of SEC sections
from mice that received MTX showing positive (+++) p53
expression (PAP · 250).
Figure 3c A photomicrograph of p53 staining of SEC sections
from mice that received VPA showing positive (++) p53
expression (PAP · 250).
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proposed to be critically involved in carcinogenesis [22]. It
was reported that during cancer growth, glutathione redox
(GSH/GSSG) decreases in the blood of Ehrlich tumour-bear-
ing mice. Glutathione reductase accounts for a very high
GSH/GSSG ratio. The decrease in glutathione reductase activ-
ity in tissues correlated well with the decrease in G6PDH activ-
ity, decreased production of NADPH and the depletion ofGSH content [23]. Cancer cells overexpress HMG-CoA reduc-
tase enzyme which is responsible for cholesterol synthesis. Ehr-
lich carcinoma had been characterized by increase cellular
content of triglycerides and cholesterol esters [18]. The chemo-
preventive activity of statins against cancer is suggested to de-
pend on inhibition of cholesterol synthesis and, thereby, cell
growth [24]. TNF-a has been found to have a pro-cancerous
effect. TNF-a produced by tumour cells or inﬂammatory cells
in the tumour microenvironment can promote tumour cell sur-
vival through the induction of genes encoding nuclear factor-
kB – dependent antiapoptotic molecules [25]. In a mouse skin
model, TNF-a induces carcinogenesis. Furthermore, gene
polymorphisms that increase or decrease TNF-a production
confer either an increased risk or protective effect on a number
of different cancers and precancerous diseases including gastric
cancer, lymphoma and cervical cancer as well as cervical intra-
epithelial neoplasia. Moreover, in murine models, TNF-a pro-
moted metastasis, tumour angiogenesis and cachexia. Trials
with anti-TNF-a therapies are awaited to block this cytokine
in patients with cancer [26].
Methotrexate (MTX) is an antimetabolite and antifolate
drug which acts by inhibiting the metabolism of folic acid. It
is known as a disease-modifying anti-rheumatic drug
(DMARD), because it not only decreases pain and swelling
of arthritis, but also can decrease damage to joints and long-
term disability. It interferes with growth of certain body cells,
especially cells that reproduce quickly, such as cancer cells,
bone marrow cells and skin cells. It is used to treat certain
types of cancer of the breast, skin, head and neck. It is also
used to treat severe psoriasis and rheumatoid arthritis [27].
In the present study, intraperitoneal administration of
MTX to mice resulted in a signiﬁcant increase in tissue catalase
and tissue glutathione reductase with a signiﬁcant decrease in
tumour volume, tissue MDA, tissue cholesterol and tissue
TNF-a and alleviated the histopathological changes with a sig-
niﬁcant increase in the expression of p53 compared to the
group that received subcutaneous implantation of Ehrlich tu-
mour cells. These results were in accordance with Srikanth
et al. [8]. MTX is thought to affect cancer by two different
pathways. It allosterically inhibits dihydrofolate reductase
(DHFR), an enzyme that participates in the tetrahydrofolate
synthesis. The afﬁnity of MTX for DHFR is about one thou-
sand-fold that of folate. DHFR catalyses the conversion of
dihydrofolate to the active tetrahydrofolate. Folic acid is
needed for the de novo synthesis of the nucleoside thymidine,
required for DNA synthesis. Also, folate is needed for purine
base synthesis, so all purine synthesis will be inhibited. So,
MTX inhibits the synthesis of DNA, RNA, thymidylates
and proteins. MTX acts speciﬁcally during DNA and RNA
synthesis and so it is cytotoxic during the S-phase of the cell
cycle [27]. Basak, et al. [28] reported that the cytotoxic effect
of MTX is associated with apoptosis enhancement, as it may
be related to hyperhomocysteinemia and deoxyribonucleotide
pool imbalances. Moreover, Winter-Vann, et al. [29] suggested
that MTX has an inhibitiory effect on Ras signalling that reg-
ulates cell growth and differentiation. Because carboxyl meth-
ylation of Ras is important for proper plasma membrane
localization and function, they reported that after MTX treat-
ment, Ras methylation was decreased by almost 90% and sub-
sequently inhibition of carboxyl methylation. Sung et al. [30]
reported that MTX suppressed the interleukin-6 induced gen-
eration of ROS and so has a protective effect against tissue
166 M.N. Abdel-Rahman, A.M. Kabeldamage induced by oxidative stress. Moreover, MTX blocks
tetrahydrofolate dependent steps in cell metabolism resulting
in adenosine overproduction which inhibits TNF-a expression
in a monocytic cell line and monocytes release adenosine after
treatment with MTX [31]. Schnyder et al. [32] reported that
application of MTX to breast cancer produced a signiﬁcant de-
crease in total cholesterol which may be due to an inhibition of
cholesterol synthesis depriving the tumour of the optimal
amounts of cholesterol needed for cell division.
Valproic acid (VPA), a well known anticonvulsive agent,
emerged as an antineoplastic agent as well, when ﬁndings indi-
cated that VPA inhibited proliferation and induced differenti-
ation of primitive neuroectodermal tumour cells in vivo [7]. In
the present study, intraperitoneal administration of VPA to
mice resulted in a signiﬁcant increase in tissue catalase and tis-
sue glutathione reductase with a signiﬁcant decrease in tumour
volume, tissue MDA, tissue cholesterol and tissue TNF-a and
alleviated the histopathological changes with a signiﬁcant in-
crease in the expression of p53 compared to the group that re-
ceived subcutaneous implantation of Ehrlich tumour cells.
The antitumour effects of VPA were attributed to the fact
that it is one of histone deacetylase (HDAC) inhibitors [7].
HDACs regulate the expression and activity of numerous pro-
teins involved in both cancer initiation and cancer progression.
HDACs bind to and deacetylate a variety of cellular proteins
including transcription factors implicated in control of cell
growth, differentiation and apoptosis [33]. It was suggested
that VPA inhibits the proliferation of malignant tumour cells
by a mechanism tightly coupled with HDAC. It was reported
that VPA down-regulates HDAC-activity in neuroblastoma
cells and so has antitumour activity [34].
Fourcade et al. [35] reported that VPA corrected the oxida-
tive damage and decreased the levels of monounsaturated very
long chain fatty acids and induced antioxidant effects in X-
linked adrenoleukodystrophy. Glauben et al. [36] demon-
strated that HDAC inhibitors including VPA suppressed cyto-
kine production (Including TNF-a) and induced apoptosis and
histone acetylation which reduced the risk of malignancies.
VPA signiﬁcantly suppressed mRNA levels of interferon-c,
TNF-a, IL-4, IL-6 and IL-17 in the lymph nodes and greatly
attenuated accumulation of macrophages, T cells and B cells
in experimental autoimmune neuritis [37].
Other studies reported that VPA is a potent inhibitor of tu-
mour angiogenesis either directly by interfering with endothe-
lial cells or indirectly by modulating tumour cells. VPA
supressed the production of angiogenesis-related growth fac-
tors. Application of VPA to the colon adenocarcinoma not
only led to a signiﬁcant reduction of vascular endothelial
growth factor (VEGF) secretion, but also to a down-regulation
of protein expression as well as VEGF coding mRNA [38].
Moreover, VPA was found to modulate the MAP kinase path-
way which plays an important role in the development of can-
cer, an effect that could be mediated through HDAC
inhibition [39]. Additionally, Beger et al. [40] reported that
VPA inhibited glycogen and RNA ribose turnover and dis-
rupted glucose-derived cholesterol synthesis in mice which will
deprive the tumour from cholesterol which is needed for tu-
mour growth. Also, HDAC inhibitors were proven to reduce
cholesterol accumulation in ﬁbroblasts [41].
In the present study, the increase in tissue catalase, tissue
glutathione reductase and p53 expression with the decrease
in tumour volume, tissue MDA, tissue cholesterol and tissueTNF-a was signiﬁcant in the group that was treated with
MTX compared to the group that received VPA. This can be
explained by the potent anti-inﬂammatory and cytotoxic ef-
fects of MTX with its ability to protect against the harmful ef-
fects of ROS, deprive the tumour of the optimal amounts of
cholesterol needed for cell division and induction of apoptosis.
In conclusion, the present study demonstrated that both
MTX and VPA have antitumour effect against solid Ehrlich
tumour in mice but MTX has the upper hand over VPA.References
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